SecBot SecBot
8-K ·Filed Nov 10, 2026

AZTA

Azenta, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed6d 7h ago SEC0001628280-26-072809
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The FY2027 guidance for 3-5% organic growth and 200-250 bps margin expansion, plus the recent Elegen/SynPlexity investments, indicate management expects a return to profitable growth. Monitor Q1 FY2027 results for execution on the organic growth trajectory and margin expansion, as well as integration progress on the new gene synthesis capabilities.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$48.90
T+0 close · Nov 10, 2026 · via day close
Latest settled
−10.31%
T+1 · $43.86
Vs SPY
−9.95%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $48.90entry
  2. T+1 · 5d ago −10.31%α −9.95% · $43.86
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Azenta reported Q4 FY2026 revenue of $167M (+5% YoY, +2% organic), slightly above the $160.2M consensus, and GAAP diluted EPS of $0.14 vs $0.11 consensus. Adjusted diluted EPS was $0.28, up 33% YoY. The company guided FY2027 revenue to $648-$660M (3-5% organic growth) and adjusted EBITDA margin expansion of 200-250 bps, signaling a stabilization and return to growth after a challenging year marked by a $149M goodwill impairment and a full-year GAAP loss.

Key Financial Metrics

EPS
$0.14
est $0.11 · +27.3%
Revenue
$167.1M
est $160.2M · +4.3% · +5.0% YoY
Rating
beat
Guidance
$648M-$660M
initiated
Free Cash Flow
$27.0M
Gross Margin
46%

Key Facts

  • Q4 FY2026 revenue $167M, up 5% YoY (organic +2%), vs consensus $160.2M
  • GAAP diluted EPS from continuing ops $0.14 vs $0.11 consensus
  • Adjusted diluted EPS $0.28, up 33% YoY from $0.21
  • FY2027 revenue guidance $648M-$660M (3-5% organic growth)
  • FY2027 adjusted EBITDA margin expansion of 200-250 bps YoY
  • Company repurchased 4.4M shares for $118.2M in FY2026; $131.8M remaining on buyback
  • Completed sale of B Medical Systems on July 1, 2026 for $63M
  • Entered Elegen license agreement ($23M fixed payments, up to $71M total) and acquired SynPlexity for $15M base cash
  • Full-year FY2026 GAAP net loss from continuing ops of $157.9M, including $149M goodwill impairment
  • Q4 adjusted EBITDA margin 11.6%, down 140 bps YoY; full-year 9.4%, down 180 bps

Financial Impact

Q4 revenue beat consensus by ~$6.8M (4.2%); adjusted EPS $0.28 vs consensus $0.11 (beat by 155%)

revenueepsguidancemarginscash flow

Segment Breakdown

SegmentRevenueGrowth
Sample Management Solutions$94.0M+9.0%
Multiomics$73.0M0.0%

Risk Factors

  • Multiomics segment organic revenue declined 1% in Q4 and was flat for the full year, indicating continued headwinds
  • Adjusted EBITDA margin contracted 140 bps in Q4 and 180 bps for the full year, despite the positive guidance
  • Elegen agreements require up to $71M in capital deployment, adding execution and integration risk
  • Full-year GAAP net loss of $157.9M driven by $149M goodwill impairment signals past overpayment for acquisitions

Market Snapshot

Exchange
Nasdaq
Sector
Special Industry Machinery, NEC
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-072809
Document: azta-20261110.htm0001628280-26-072809
Document: 0001628280-26-072809-index-headers.html0001628280-26-072809
Document: 0001628280-26-072809-index.html0001628280-26-072809
Document: 0001628280-26-072809.txt0001628280-26-072809
8-K Data (Synthetic)0001628280-26-072809

Track record

12 reports on AZTA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +29.70% at T+60 after the Aug 4, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Bullish 6/10 Viewing Entry $48.90 Now $47.22 −3.44% settles Nov 18
  2. Oct 30, 202617d ago 8-K Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
  3. Oct 30, 202617d ago Press Release Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
  4. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $35.89 to $37.18 Now $47.22 −31.57% ▼ −3.59% −4.57% vs SPY
  5. Sep 17, 20268w ago 8-K Neutral 2/10 Entry $33.63 to $34.20 Now $47.22 +40.41% ▲ +1.69% +1.09% vs SPY
  6. Sep 4, 202610w ago 8-K Neutral 4/10 Entry $31.33 to $32.04 Now $47.22 +50.72% ▲ +2.27% +3.48% vs SPY
  7. Aug 24, 202612w ago 8-K Neutral 4/10 Entry $32.88 to $32.65 Now $47.22 +43.61% ▼ −0.70% −1.17% vs SPY
  8. Aug 8, 202614w ago Institutional Cluster Mixed 5/10 Entry $33.33 to $33.58 Now $47.22 +41.67% ▲ +0.75% +0.80% vs SPY
  9. Aug 4, 202614w ago Press Release Bullish 7/10 Entry $31.82 to $33.53 Now $47.22 +48.40% ▲ +5.37% +5.02% vs SPY
  10. Jul 8, 202618w ago 8-K Mixed 5/10 Entry $24.51 to $25.44 Now $47.22 +92.66% ▲ +3.79% +2.93% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (9h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026